Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre-Specified Secondary Analysis of the TVFR Trial.
Clin Endocrinol (Oxf)Aug 3, 2026 (epub)
Annabelle M Warren, Kay Weng Choy, Rudolf Hoermann et al.
✦ AI-curated · Sources linked
In 30 seconds
This study analyzed the effects of tolvaptan on serum copeptin levels in hospitalized patients with hyponatraemia, as part of a pre-specified secondary analysis of a randomized controlled trial. The results showed that tolvaptan significantly increased copeptin levels by a mean adjusted difference of 8.4 pmol/L compared to fluid restriction, although baseline copeptin did not predict rapid sodium rise.
Key findings
- Tolvaptan increased serum copeptin by a mean adjusted difference of 8.4 pmol/L compared to fluid restriction.
- Copeptin levels remained stable after fluid restriction.
- Baseline copeptin did not predict rapid sodium rise in patients.
Why it matters
Understanding the relationship between copeptin and treatment outcomes in hyponatraemia could inform clinical decision-making. The increase in copeptin after tolvaptan may reflect physiological responses that warrant further investigation.